October 19, 2015.
Daiichi Sankyo will "reorganize its U.S. Commercial organization as it transfers to a differentiated specialty portfolio that will include areas such as cardiovascular, pain management and oncology", the company has announced.
The company says it "will reduce expenses, including a reduction in headcount, from its U.S. Commercial operations". It expects to eliminate 1,000 to 1,200 positions across the country, from the Commercial Home Office, located in Parsippany, NJ, and field-based sales and other positions throughout the country. The company added that the reorganization is not focused on the U.S.-based R&D function concentrated in Edison, NJ, or the packaging plant in Bethlehem, PA.
Can Data and AI Deliver Whole-Person Health?
July 9th 2024Executives in the life sciences and medical device industries see promise in artificial intelligence (AI) and medical technologies, but must also navigate the changing healthcare ecosystem, varied stakeholder needs, and the impact of AI on market access and commercialization strategies.